# Adcendo

Source: https://onco.cc/companies/adcendo/  
OnCo record `adcendo` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adcendo is a Danish company developing antibody-drug conjugates, antibodies that deliver a cell-killing drug straight to cancer cells, against targets few others are pursuing. Its first medicines are in early human trials, including one for soft tissue sarcoma.

## Summary

Adcendo ApS is a clinical-stage Copenhagen biotech developing antibody-drug conjugates against targets, such as tissue factor and uPARAP, that few other companies pursue. Its pipeline comprises ADCE-T02, a tissue factor-targeted ADC in the phase 1 Tiffany-01 study (cohort expansion in multiple solid tumour indications from April 2026, with a pembrolizumab combination cohort agreed with MSD in May 2026); ADCE-D01, a uPARAP-targeted ADC in the ADCElerate1 dose escalation and expansion study in soft tissue sarcoma and other mesenchymal cancers; and ADCE-B05, against an undisclosed target, in dose escalation in squamous cell carcinomas. The company closed an oversubscribed USD 135 million Series B in November 2024 led by TCGX, and a USD 75 million Series C in April 2026 led by Jeito Capital with Vida Ventures, Bpifrance and EIFO joining existing investors including RA Capital, Novo Holdings and Ysios Capital.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Copenhagen
- Type: biotech
- Website: https://adcendo.com/

## Notes

- Earlier Series A (2021) not fetched and omitted. Founding year not stated on fetched pages.

## Sources

- Official website: https://adcendo.com/
- Series B press release: https://adcendo.com/adcendo-aps-completes-oversubscribed-135-million-series-b-financing-to-advance-first-in-class-adc-pipeline/
- Series C press release: https://adcendo.com/adcendo-aps-completes-75-million-series-c-financing-to-continue-advancing-first-and-best-in-class-clinical-adc-pipeline/

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [Tissue factor](https://onco.cc/targets/tissue-factor/)
- trials: [First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma](https://onco.cc/trials/nct06797999/)
- companies: [Bpifrance](https://onco.cc/companies/bpifrance/), [Gilde Healthcare](https://onco.cc/companies/gilde-healthcare/), [Jeito Capital](https://onco.cc/companies/jeito-capital/), [Logos Capital](https://onco.cc/companies/logos-capital/), [Novo Holdings](https://onco.cc/companies/novo-holdings/), [OrbiMed](https://onco.cc/companies/orbimed/), [RA Capital Management](https://onco.cc/companies/ra-capital/), [TCGX (TCG Crossover)](https://onco.cc/companies/tcgx/), [Venrock](https://onco.cc/companies/venrock/), [Vida Ventures](https://onco.cc/companies/vida-ventures/)

---
JSON: https://onco.cc/api/v1/entities/adcendo.json